Compared with the presurgical levels, serum levels of TYMS-AAb, IGFBP5-AAb, and HAPLN1-AAb decrease at 3 months after surgery and remain low up to one year, implying a possibility of utilizing CMT-associated AAbs for predicting tumor recurrence or treatment responses. The gene discussed is TYMS; the disease is neoplasm.